Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new partnership has been formed between European and African researchers to develop an AIDS vaccine that can be used to prevent infection with different strains of HIV worldwide.

The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) will evaluate a new vaccine that triggers the body to produce specialised immune cells called T-cells, which will be trialled at four sites in Kenya, Uganda and Zambia.

Led by Professor Tomáš Hanke at the Jenner Institute at University of Oxford, GREAT is a collaboration between Oxford University, Imperial College London, the International AIDS Vaccine Initiative (IAVI), the Kenya AIDS Vaccine Initiative - Institute for Clinical Research (KAVI-ICR), The Kenya Medical Research Institute - Wellcome Trust Research Programme (KWTRP), the Medical Research Council at the Uganda Virus Research Institute (MRC/UVRI), UVRI-IAVI and the Zambia Emory HIV Research Program (ZEHRP).

Read more

Similar stories

Parental mental health worsens under new national COVID-19 restrictions

Coronavirus COVID-19 General Research

Parental stress, depression and anxiety have again increased since new national restrictions have been introduced, according to the latest report from the Oxford University-led COVID-19 Supporting Parents, Adolescents, and Children in Epidemics (Co-SPACE) study, based on data from over 6000 UK parents.

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

National consortium to study threats of new SARS-CoV-2 variants

Coronavirus COVID-19 General Research

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

Immunology preprint reviews launched in Nature Reviews Immunology

General Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

General Research

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.